![](https://scx1.b-cdn.net/csz/news/tmb/2021/rybrevant-approved-for.jpg)
Rybrevant approved for some non-small cell lung cancer patients
Rybrevant (amivantamab-vmjw) was approved for adults with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, the U.S. Food and Drug Administration announced Friday.
May 26, 2021
0
1